Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • CDK
    (39)
  • GSK-3
    (14)
  • Apoptosis
    (12)
  • Aurora Kinase
    (2)
  • FAK
    (2)
  • PKC
    (2)
  • PYK2
    (2)
  • Aryl Hydrocarbon Receptor
    (1)
  • Autophagy
    (1)
  • Others
    (15)
Filter
Search Result
Results for "

cdk1/cyclinb

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    60
    TargetMol | Inhibitors_Agonists
  • PROTAC Products
    2
    TargetMol | PROTAC
  • Natural Products
    1
    TargetMol | Natural_Products
r547
Ro 4584820
T6312741713-40-6In house
R547 (Ro 4584820) is a potent ATP-competitive inhibitor of CDK1 2 4 with Ki of 2 nM 3 nM 1 nM. It is less potent to CDK7 and GSK3α β, while inactive to other kinases. Phase 1.
  • Inquiry Price
Size
QTY
KenPaullone
NSC-664704, 9-Bromopaullone
T2247142273-20-9
KenPaullone (9-Bromopaullone), a potent CDK1, CDK2 and CDK5 inhibitor, as new enhancer for iTreg cell differentiation. Kenpaullone promotes iTreg cell differentiation through increased and prolonged transcription of foxp3 gene by enhancing TGFβ-Smad3 signaling pathway.
  • Inquiry Price
Size
QTY
TargetMol | Citations Cited
pha-793887
PHA793887, PHA 793887
T2113718630-59-2
PHA-793887 has been used in trials studying the treatment of Advanced Metastatic Solid Tumors.
  • Inquiry Price
Size
QTY
TargetMol | Citations Cited
MeBIO
T21966667463-95-8
MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1 CyclinB, respectively. MeBIO does not affect GSK-3β.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
riviciclib hydrochloride
P276-00
T6924920113-03-7
Riviciclib hydrochloride (P276-00) is a novel inhibitor of CDK1, CDK4, and CDK9, with IC50 values of 79 nM, 63 nM, and 20 nM, respectively, currently in Phase 2 3.
  • Inquiry Price
4-6 weeks
Size
QTY
JNJ-7706621
JNJ 7706621
T6126443797-96-4
JNJ-7706621 is a potent aurora kinase inhibitor that also inhibits CDK1 and CDK2.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Indirubin-3'-monoxime
Indirubin-3'-oxime
T5200160807-49-8
Indirubin-3'-monoxime (Indirubin-3'-oxime) is a potent inhibitor of GSK3β (IC50: 22 nM) and also inhibits CDKs ( (IC50s: 100 180 250 nM for Cdk5 p35, Cdk1 cyclin B, Cdk2 cyclin E).
  • Inquiry Price
Size
QTY
NU6102
NU-6102, NU 6102
T28218444722-95-6In house
NU6102 is a selective and potent ATP-competitive CDK2 inhibitor with antitumor activity against CDK1 cyclinB, CDK2 cyclinA3, CDK1 CDK2, CDK4, DYRK1A , PDK1, and ROCKII, and it can be used to study rectal cancer.
  • Inquiry Price
7-10 days
Size
QTY
NVP-LCQ195
AT9311, LCQ-195
TQ0068902156-99-4In house
NVP-LCQ195 (LCQ-195) (AT9311) is a potent inhibitor of CDK1, CDK2, CDK3 and CDK5 (IC50: 1-42 nM).
  • Inquiry Price
Size
QTY
GP-82996
CINK4, Cdk4 6 Inhibitor IV
T21720359886-84-3In house
GP-82996 (CINK4) is a pharmacological inhibitor specifically targeting CDK4 6, exhibiting IC50 values of 1.5 μM for CDK4 cyclin D1, 5.6 μM for CDK6 cyclin D1, and 25 μM for Cdk5 p35. It effectively induces apoptosis in U2OS cancer cells, positioning it as a potential investigational tool in cancer research [1] [2].
  • Inquiry Price
7-10 days
Size
QTY
5-Iodo-indirubin-3'-monoxime
T10172331467-03-9In house
5-Iodo-indirubin-3'-monoxime is a potent inhibitor of GSK-3β, CDK5 P25, and CDK1 cyclin B, competing with ATP for binding to the catalytic site of the kinase (IC50s: 9, 20, and 25 nM).
  • Inquiry Price
6-8 weeks
Size
QTY
Cdk1/2 Inhibitor III
T14914443798-55-8In house
Cdk1 2 Inhibitor III is a selective inhibitor of Cdk1 2 with an IC50 value of 2.1 μM against CDK1 cyclin B.
  • Inquiry Price
8-10weeks
Size
QTY
BMS-265246
BMS265246
T2679582315-72-8
BMS-265246 is a potent and selective CDK1 2 inhibitor. Its chemical name is (4-[R-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-1H-indol-1-yl]-1H-pyrazolo[3,4-d] pyrimidine-6-amine), and it functions by targeting CDK1 and CDK2 to potentially disrupt cell cycle progression.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
bs-181
BS 181
T19471092443-52-1
BS-181 is a highly selective CDK7 inhibitor (IC50: 21 nM); >40-fold selective for CDK7 than CDK1 2 4 5 6 9.
  • Inquiry Price
6-8 weeks
Size
QTY
TargetMol | Citations Cited
CVT-313
NG26, CVT313, CVT 313, Cdk2 Inhibitor III
T3195199986-75-9
CVT-313 (NG-26) is a potent, selective, reversible, and ATP-competitive inhibitor.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
AT7519
T6205844442-38-2
AT7519 is a CDK1 2 4 6 9 inhibitor (IC50: 10-210 nM). It is less effective to CDK3 and little active to CDK7.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
GSK 3 Inhibitor IX
6-bromoindirubin-3-oxime, BIO, 6-Bromoindirubin-3'-oxime, GSK 3 IX, 6-BIO, MLS 2052
T1917667463-62-9
GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α β and CDK1-cyclinB complex. It inhibits (GSK-3α β) CDK1 CDK5 activity with IC50 values of 5 nM 320 nM 83 nM, respectively.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
cct245737
SRA737
T70801489389-18-5
CCT245737 is an orally active, selective Chk1 inhibitor with an IC50 of 1.3 nM, and is >1,000-fold selective over CHK2 and CDK1.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
PF-562271
PF562271, PF 562271
T2465717907-75-0
PF-562271 is an effective ATP-competitive, reversible inhibitor of FAK(IC50=1.5 nM) and Pyk2 kinase(IC50=13 nM).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
Milciclib
PHA-848125
T6081802539-81-7
Milciclib (PHA-848125) (PHA-848125) is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. Phase 2.
  • Inquiry Price
Size
QTY
TargetMol | Citations Cited
PF-562271 besylate
PF-00562271 Besylate
T6177939791-38-5
PF-562271 besylate (PF-00562271 Besylate) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
can508
T8796140651-18-9
CAN508 is a potent ATP-competitive CDK9 cyclin T1 inhibitor with an IC50 of 0.35 μM. It also competitively inhibits Cdk2-cyclin E with respect to ATP, with Ki and IC50 values of 13.3 μM and 20 μM, respectively. CAN508 exhibits a 38-fold selectivity for CDK9 cyclin T over other CDK cyclin complexes. [Antitumor activity.]
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
JSH-0009 dimaleate
T881702559759-04-3
  • Inquiry Price
10-14 weeks
Size
QTY
Aloisine A
T21377496864-16-5
Aloisine A is a potent and selective CDK/GSK-3 inhibitor. IC50 data of Aloisine A: Cdk1/cyclin B (IC50: 150nM), Cdk2/cyclin A (IC50: 120nM), Cdk2/cyclin E (IC50: 400nM), Cdk5/p25 (IC50: 200nM), Cdk5/p35 (IC50: 160nM), GSK-3α (IC50: 500nM), GSK-3β (IC50: 6
  • Inquiry Price
6-8 weeks
Size
QTY